Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paroxetine treatment during 8 weeks · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| arm 1 | ACTIVE_COMPARATOR | Paroxetine treatment during 8 weeks |
| arm 2 | PLACEBO_COMPARATOR | Placebo treatment during 8 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo treatment during 8 weeks | DRUG | comparator |
| Paroxetine treatment during 8 weeks | DRUG | treatment drug |
Inclusion criteria: * Outpatient with Social Anxiety Disorder * The subject is healthy * Willing to restrict alcohol intake * Capable of giving informed consent Exclusion criteria: * Subjects with depression or any other psychiatric condition * Subjects positive for HIV or hepatitis * Subjects ta...
Paroxetine treatment during 8 weeks refers to an 8-week course of the small molecule paroxetine, developed by GSK plc (ticker GSK), studied in a Phase 1 trial for social phobia, also called social anxiety disorder. The trial was randomized, double-blind, and placebo-controlled, enrolling 56 participants in Spain.
Paroxetine targets SLC6A4, the serotonin transporter, and acts as an inhibitor of this target. By inhibiting SLC6A4, paroxetine affects serotonergic signaling, which is the mechanism explored in its clinical development for psychiatric conditions such as social phobia.
GSK plc, which trades under the ticker GSK, is the developer of paroxetine treatment during 8 weeks. GSK sponsored the Phase 1 study of this small molecule in social phobia, and the company is identified as the developer of the asset.
Paroxetine treatment during 8 weeks is in Phase 1 development. The single listed trial, NCT00470483, is a completed Phase 1 study. The drug is investigational and is not described as approved for social phobia based on this development program.
Paroxetine treatment during 8 weeks has been studied in one clinical trial, NCT00470483, titled A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder. This completed Phase 1 trial enrolled 56 participants in Spain, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.